Animet Tablet 50/500 mg
Sitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 505mg
Tablet · Prescription medication · Combination
Kujoo Pharmaceutical Co., Ltd.
MFDS item code 202200619 · Approved 2022.02.08
Improvement of glycemic control in type 2 diabetes
This medicine is used to improve blood sugar control in patients with type 2 diabetes when used in conjunction with diet and exercise. It is particularly prescribed for patients who have not previously received diabetes medication and find it difficult to control blood sugar with monotherapy. Furthermore, if blood sugar control is insufficient with monotherapy using metformin or sitagliptin, this medicine can provide more effective management. For patients who are already having difficulty managing blood sugar with a combination of metformin and sulfonylureas, thiazolidinediones, or insulin, this medicine can enhance treatment efficacy when used in combination. In summary, this medicine improves blood sugar control when used alone or in combination with various diabetes medications.
For antidiabetic therapy, the dose of this medicine should be determined based on each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This medicine is generally taken twice daily with meals. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. The initial dose of this medicine is determined according to the patient’s current treatment regimen. 1. Patients not currently receiving metformin: For patients with no previous history of antidiabetic drug treatment whose blood glucose is not adequately controlled with monotherapy, or whose blood glucose cannot be adequately controlled with sitagliptin monotherapy, the initial dose is 1 tablet of this medicine 50/500 mg twice daily. The dose may be increased to 1 tablet of this medicine 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine (see Precautions for Use, 2. Do not administer to the following patients). 2. Patients receiving metformin: - For patients whose blood glucose is not adequately controlled with metformin monotherapy, the recommended initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg) and the patient’s current metformin dose. - Patients switching from concomitant sitagliptin and metformin therapy to this medicine may start at their current doses of sitagliptin and metformin. 3. Patients whose blood glucose is not adequately controlled with concomitant metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg). The initial dose of metformin should take into account the patient’s blood glucose level and current dose. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. When used concomitantly with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with another oral antihyperglycemic agent to this medicine. Any change in treatment for type 2 diabetes may alter blood glucose control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Since the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment Due to its metformin component, this medicine should not be administered to patients with hepatic impairment (see Precautions for Use, 2. Do not administer to the following patients).
This medicine contains two ingredients: sitagliptin and metformin, which are antidiabetic agents. First, serious allergic reactions may occur during treatment with this medicine; therefore, discontinue use immediately and inform medical staff if symptoms such as skin rash, difficulty breathing, or swelling of the face or neck occur. Second, pancreatitis, an inflammation of the pancreas, can occur rarely; therefore, if symptoms such as abdominal pain, nausea, vomiting, or fever arise, visit a hospital immediately. Third, due to the metformin component, lactic acidosis, a rare but potentially fatal metabolic disorder, can occur; hence, inform medical personnel immediately if sudden fatigue, muscle pain, difficulty breathing, or abdominal pain occurs. Fourth, this medicine should not be used by patients with moderate to severe renal impairment, acute heart failure, severe infections, or those who are pregnant or breastfeeding. Fifth, regular monitoring of renal function and blood tests is required while using this medicine, especially in elderly patients or those with weakened renal function. Sixth, this medicine may cause hypoglycemia; caution should be taken when skipping meals or engaging in strenuous exercise, as the risk of hypoglycemia may increase when taken with other hypoglycemic agents. Seventh, alcohol consumption can increase the risk of lactic acidosis, so it is advisable to avoid drinking while taking this medication. Eighth, patients scheduled for surgery should discontinue this medicine 48 hours before surgery and may resume use after renal function is confirmed to be normal post-surgery. Ninth, if blisters or severe joint pain occur while taking this medicine, notify medical staff immediately. Finally, the safety and efficacy of this medicine in children and adolescents have not been established, so it should not be used in these populations.
Anaphylaxis, angioedema, Stevens-Johnson syndrome, acute pancreatitis, lactic acidosis, hypoglycemia, diarrhea, upper respiratory infection, headache, nausea, vomiting, abdominal pain, nasopharyngitis, constipation, arthralgia with severe and disabling symptoms, bullous pemphigoid, myalgia, limb pain, back pain, interstitial lung disease, pruritus, thrombocytopenia, rash, urticaria, cutaneous vasculitis, elevated liver enzymes, acute renal failure, dyspnea, unstable angina, dizziness, decreased appetite, itching, anorexia, weight loss, decreased serum vitamin B12, dermatitis
Not everyone experiences these, and they can vary from person to person.
This medicine should be stored in an airtight, sealed container, ideally at room temperature between 1 and 30 degrees Celsius. Storing it this way will help maintain the medicine's effectiveness and prevent deterioration.
Bright pink oval film-coated tablets
30 tablets/box [(10 tablets/PTP x 3)]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Sitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 505mg
Tablet · Prescription medication · Combination
Kujoo Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 858.5mg
Tablet · Prescription medication · Combination
Daewon Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 1010mg
Tablet · Prescription medication · Combination
Daewon Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 505mg
Tablet · Prescription medication · Combination
Daewon Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 505mg
Tablet · Prescription medication · Combination
Samsung Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 858.5mg
Tablet · Prescription medication · Combination
Samsung Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 1010mg
Tablet · Prescription medication · Combination
Samsung Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 1010mg
Tablet · Prescription medication · Combination
Eden Pharma Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.